(Total Views: 551)
Posted On: 11/01/2019 7:17:28 PM
Post# of 154238
trding,
Yes, this is interesting and, in a way, lends credence to the model of operation of Leronlimab.
Patients with a mutated CCR5 (delta 32) will not bind to the HIV virus, a CCR5 antagonist like Lero as well binds to the CCR5 stopping the invasion of the virus.
Arguably (here I am talking with complete ignorance) a patient with full occupancy would be reacting like a CCR5-Delta 32 patient ?? (of course, the patient with a permanently mutated gene does not have to do anything whereas the other will need to take the proper amount of Lero to achieve the same result).
IMIO (In My Ignorant Opinion).
Yes, this is interesting and, in a way, lends credence to the model of operation of Leronlimab.
Patients with a mutated CCR5 (delta 32) will not bind to the HIV virus, a CCR5 antagonist like Lero as well binds to the CCR5 stopping the invasion of the virus.
Arguably (here I am talking with complete ignorance) a patient with full occupancy would be reacting like a CCR5-Delta 32 patient ?? (of course, the patient with a permanently mutated gene does not have to do anything whereas the other will need to take the proper amount of Lero to achieve the same result).
IMIO (In My Ignorant Opinion).
(0)
(0)
